Michael Hallek to Risk
This is a "connection" page, showing publications Michael Hallek has written about Risk.
Connection Strength
0.018
-
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017 12; 31(12):2833-2837.
Score: 0.018
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.